A Phase 0 Window of Opportunity Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Patients with Recurrent Gliomas.

Saved in:
Bibliographic Details
Title: A Phase 0 Window of Opportunity Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Patients with Recurrent Gliomas.
Authors: Burton EC; Neuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892., Walker E; Neurosurgical Oncology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1414., Boris L; Neuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892., Reyes J; Neuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892., Fernandez K; Neuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892., Wall K; Neuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892., Wu J; Neuro-oncology Branch, National Cancer Institutes, 9030 Old Georgetown Road, Building 82, Bethesda, MD 20892., Schmidt KT; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Besthesda, MD 20892., Figg WD; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Besthesda, MD 20892., Brown DA; Neurosurgical Oncology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1414.
Source: MedRxiv : the preprint server for health sciences [medRxiv] 2025 Aug 21. Date of Electronic Publication: 2025 Aug 21.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
DOI:10.1101/2025.08.18.25333496